EUCTR2011-003212-22-GB进行中（未招募）1 期
Phase I study of ex-vivo lentiviral gene therapy for the inherited skin disease Netherton Syndrome - Gene Therapy for Netherton Syndrome
GOSH/ICH Joint Research & Development Office0 个研究点目标入组 5 人开始时间: 2013年3月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Confirmed SPINK5 mutations in both alleles by direct DNA sequencing
- •2. Absence of LEKTI protein expression in the skin by in situ immunostaining
- •3. Patient informed consent, or parental/guardian consent in the case of minor
- •participant
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 2
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 3
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. History of skin malignancy or evidence of current active malignant skin disease
- •2. Pregnancy
- •3. Hepatitis A, B, C or HIV positive
- •4. Current antibiotic resistant bacterial colonisation
研究者
相似试验
进行中（未招募）
1 期
Phase I/II ex vivo gene therapy clinical trial for RDEB using autologous skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector - EBGraftThe trial aims to treat the recessive dystrophic epidermolysis bullosa (RDEB) by grafting one to three subjects with RDEB with autologous COL7A1-modified skin equivalents, using SIN-RV encoding COL7A1 cDNA.MedDRA version: 20.0 Level: LLT Classification code 10074980 Term: Epidermolysis bullosa aquisita System Organ Class: 100000004858EUCTR2016-002790-35-FRINSERM3
进行中（未招募）
1 期
Clinical study to assess the efficacy and safety of gene therapy for the treatment of Sickle Cell DiseaseMedDRA version: 21.0Level: PTClassification code 10040644Term: Sickle cell diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersSickle Cell DiseaseEUCTR2019-000331-63-FRbluebird bio, Inc.35
进行中（未招募）
1 期
Clinical study to assess the efficacy and safety of gene therapy for the treatment of Sickle Cell DiseaseSickle Cell DiseaseEUCTR2019-000331-63-NLbluebird bio, Inc.35
进行中（未招募）
1 期
Clinical study to assess the efficacy and safety of gene therapy for the treatment of Sickle Cell DiseaseMedDRA version: 21.0Level: PTClassification code 10040644Term: Sickle cell diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersSickle Cell DiseaseEUCTR2019-000331-63-ITBLUEBIRD BIO, INC.35
进行中（未招募）
1 期
Clinical study to assess the efficacy and safety of gene therapy for the treatment of Sickle Cell DiseaseMedDRA version: 21.0Level: PTClassification code 10040644Term: Sickle cell diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersSickle Cell DiseaseEUCTR2019-000331-63-GBbluebird bio, Inc.35